New York State Common Retirement Fund Sells 15,584 Shares of CareDx, Inc (NASDAQ:CDNA)

New York State Common Retirement Fund lessened its stake in CareDx, Inc (NASDAQ:CDNA) by 48.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,339 shares of the company’s stock after selling 15,584 shares during the quarter. New York State Common Retirement Fund’s holdings in CareDx were worth $350,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Virtue Capital Management LLC acquired a new position in shares of CareDx during the third quarter worth about $755,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of CareDx during the third quarter worth about $1,671,000. Geode Capital Management LLC boosted its position in shares of CareDx by 2.7% during the third quarter. Geode Capital Management LLC now owns 1,227,724 shares of the company’s stock worth $38,343,000 after buying an additional 32,141 shares during the period. Hanseatic Management Services Inc. acquired a new position in shares of CareDx during the third quarter worth about $781,000. Finally, Barclays PLC boosted its position in shares of CareDx by 123.8% during the third quarter. Barclays PLC now owns 98,505 shares of the company’s stock worth $3,075,000 after buying an additional 54,482 shares during the period.

CareDx Trading Down 3.9 %

Shares of NASDAQ CDNA opened at $20.30 on Wednesday. The firm has a market cap of $1.09 billion, a P/E ratio of -7.52 and a beta of 1.87. CareDx, Inc has a 1-year low of $7.42 and a 1-year high of $34.84. The business’s 50 day moving average is $22.70 and its 200-day moving average is $25.14.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm had revenue of $86.58 million for the quarter, compared to analyst estimates of $84.56 million. Analysts forecast that CareDx, Inc will post -0.9 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Wells Fargo & Company raised CareDx from an “underweight” rating to an “equal weight” rating and reduced their price target for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. Stephens restated an “overweight” rating and issued a $40.00 price objective on shares of CareDx in a research note on Thursday, February 27th. HC Wainwright dropped their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating on the stock in a research note on Monday. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a research note on Wednesday, February 26th. Finally, BTIG Research dropped their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Tuesday, November 5th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, CareDx has a consensus rating of “Moderate Buy” and an average price target of $31.83.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.